%0 Journal Article
%A Quiroga, Borja
%A Soler, Maria Jose
%A Ortiz, Alberto
%A Orero, Esther
%A Tejedor, Sandra
%A Jarava-Mantecon, Carlos Jesus 
%A Gomez-Perez, Virginia Olinda
%A Marin-Franco, Antonio Jose
%A Alfaro-Sanchez, Christian
%A Puerta-Carretero, Marta
%A Jaldo-Rodriguez, Maria Teresa
%A Carnerero-Di-Riso, Manuel Antonio
%A Martinez, Shaira
%A Caldeon-Gonzalez, Carmen 
%A Cervienka, Michal
%A Macias-Carmona, Nicolas
%A Arroyo, David
%A Perez-Del-Valle, Katia M
%A de-Arriba, Gabriel
%A Mazuecos, Auxiliadora
%A Cazorla, Juan Manuel
%A Pereira, Monica
%A Gonzalez-Parra, Emilio
%A Sanchez-Marquez, Maria Gabriela
%A Lancho-Novillo, Carolina
%A Toyos-Ruiz, Carmen
%A Aguilar-Cervera, Maria Cinta
%A Muñoz-Ramos, Patricia
%A Sanchez-Horrillo, Ana
%A Jimeno-Martin, Isabel
%A Toapanta, Nestor
%A Cigarran-Guldris, Secundino
%A Folgueiras-Lopez, Montserrat
%A Valero-San-Cecilio, Rosalia
%A Villacorta-Linaza, Blanca
%A Minguela-Pesquera, Ignacio
%A Santana-Estupiñan, Raquel
%A Zamora, Rocio
%A Soriano, Sagrario
%A Muñoz-de-Bustillo, Eduardo
%A Pizarro-Sanchez, Maria Soledad
%A Martinez-Puerto, Ana Isabel
%A Yugueros, Alejandra
%A Muñiz-Pacios, Laura
%A Leyva, Alba
%A Rojas, Jose
%A Gansevoort, Ron T
%A de-Sequera, Patricia
%T Humoral Response to Third Dose of SARS-CoV-2 Vaccines in the CKD Spectrum.
%D 2022
%U http://hdl.handle.net/10668/20489
%X Information on the effect of a third dose of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccine in advanced CKD is incomplete (1). We assessed the humoral response up to 6 months after receipt of two or three doses of the SARS-CoV-2 vaccine across the CKD spectrum. SENOVAC is a prospective, multicentric study of cohorts of patients with CKD: kidney transplant, hemodialysis (HD), peritoneal dialysis (PD), and nondialysis CKD (eGFR <30 ml/min per 1.73 m2) (2,3). Patients were vaccinated against SARS-CoV-2 during routine clinical care. Some patients received a third dose of an mRNA vaccine. This depended on the timing of vaccination drives by local health authorities. We assessed anti-Spike antibodies (CLIA, Covid-19 Spike Quantitative Virla IgG Monotest; Vircell SL, Spain) kinetics at a prespecified 6-month time point after completing the original vaccination schedule (2,3). The study was approved by the ethics committee of Instituto de Investigación Sanitaria-Fundación Jiménez Díaz (ISFJD) (February 2021).
%K COVID-19
%K SARS-CoV-2
%K Anti-Spike
%K Chronic kidney disease
%K Hemodialysis
%K Kidney transplantation
%K Peritoneal dialysis
%K Vaccination
%~